← Back to Search

Unknown

S-217622 for Kidney Failure

Phase 1
Waitlist Available
Research Sponsored by Shionogi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 (predose) up to 336 hours postdose on day 1 to day 15
Awards & highlights

Study Summary

This trial is testing a new drug to see how well it works and how safe it is for people with different levels of kidney function.

Eligible Conditions
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 (predose) up to 336 hours postdose on day 1 to day 15
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 (predose) up to 336 hours postdose on day 1 to day 15 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Apparent Total Clearance (CL/F) of S-217622
Apparent Volume of Distribution (Vz/F) of S-217622
Area Under the Plasma Concentration-Time Curve (AUC) of S-217622
+8 more
Secondary outcome measures
Number of Participants with Treatment-Emergent Adverse Events

Trial Design

4Treatment groups
Experimental Treatment
Group I: S-217622: Group DExperimental Treatment1 Intervention
Participants with normal renal function will receive a single dose of S-217622 on Day 1, in a fasted state.
Group II: S-217622: Group CExperimental Treatment1 Intervention
Participants with severe renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
Group III: S-217622: Group BExperimental Treatment1 Intervention
Participants with moderate renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
Group IV: S-217622: Group AExperimental Treatment1 Intervention
Participants with mild renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
S-217622
2022
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

ShionogiLead Sponsor
115 Previous Clinical Trials
41,229 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
2022. "A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05363215.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top